August 8, 2014, Newberry, FL - eTect, Inc. has been awarded a $1 million contract by the National Institute on Drug Abuse (NIDA) to continue developing the ID-Cap system. Under the contract, which is Phase II of an earlier project, eTect will utilize the ID-Cap system in a trial of non-treatment seeking marijuana dependent subjects.
In 2012, eTect was awarded a Phase I Small Business Innovative Research contract to add key compliance features to the prototype ID-Cap system to assess medication adherence. During the six-month contract, eTect met and exceeded their goals by demonstrating that ID-Cap can provide an accurate measurement of medication adherence.
ID-Cap is a medicine capsule with an embedded ingestible wireless sensor. When a patient takes their medicine contained in an ID-Cap, the capsule emits a low power wireless signal from inside the patient to indicate ingestion.
As a part of the Phase II program, eTect will add biometric identification capabilities to their current ID-Cap reader and incorporate a secure backend software platform that will support the most stringent government security requirements. Dr. Aimee McRae of The Medical University of South Carolina will implement the 40 patient clinical trial with marijuana dependent subjects.
"NIDA has been an instrumental partner in developing the ID-Cap technology and our continued association with them greatly enhances our ability to improve medication compliance in clinical research. Phase II of the program will allow us to refine the ID-Cap system and expand upon the secure data communication channel," said Dr. Chris Carnes, Chief Information Officer at eTect, Inc and the principal investigator of this project.
About this Project
This project has been funded in whole or in part with Federal funds from the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN271201400032C (NIDA Reference No. N44DA-14-2232).
About The National Institute on Drug Abuse (NIDA)
The National Institute on Drug Abuse (NIDA) is a United States federal-government research institute whose mission is to "lead the Nation in bringing the power of science to bear on drug abuse and addiction." For more information, visit their website at www.drugabuse.gov.
About eTect, Inc.
eTect, Inc. is a specialized communications technology company that develops applications for its novel in-vivo wireless communications platform. The company's flagship product is an innovative mobile platform that will provide a deeper understanding of patient's medication taking behavior leading to better care, lower cost, and improved outcomes. The company brings together a diverse collection of world class talent in signal processing, in-vivo communications, advanced materials, and integrated circuit design. For more information visit our website at www.etectbio.com.
For more information on this press release, please contact:
President, Buzz Marketing
Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.